Napo pharmaceuticals surveys of neurologists, patients, and caregivers regarding amyotrophic lateral sclerosis (als) treatment indicate real world burden of diarrhea and potential treatment interruption

Jaguar health family company napo pharmaceuticals focuses on essential supportive care and management of neglected toxicities in multiple complicated disease states san francisco, ca / accesswire / august 16, 2023 / napo pharmaceuticals, inc. (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that the results of a napo-sponsored survey of 15 us neurologists who treat patients with amyotrophic lateral sclerosis (als), and the results of a corresponding napo-sponsored survey of 15 us individuals who are either als patients or caregivers of an als patient, indicate that the burden of diarrhea associated with a commonly used treatment ("the als drug") for this rare progressive neurodegenerative disease may be higher than previously understood. napo focuses on essential supportive care and management of neglected toxicities in multiple complicated disease states.
JAGX Ratings Summary
JAGX Quant Ranking